A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
* These authors contributed equally
His-tag purification, dialysis, and activation are employed to increase yields of soluble, active matrix metalloproteinase-3 catalytic domain protein expression in bacteria. Protein fractions are analyzed via SDS-PAGE gels.
Matrix metalloproteinases (MMPs) belong to the family of metzincin proteases with central roles in extracellular matrix (ECM) degradation and remodeling, as well as interactions with several growth factors and cytokines. Overexpression of specific MMPs is responsible in several diseases such as cancer, neurodegenerative diseases, and cardiovascular disease. MMPs have been the center of attention recently as targets to develop therapeutics that can treat diseases correlated to MMP overexpression.
To study the MMP mechanism in solution, more facile and robust recombinant protein expression and purification methods are needed for the production of active, soluble MMPs. However, the catalytic domain of most MMPs cannot be expressed in Escherichia coli (E. coli) in soluble form due to lack of posttranslational machinery, whereas mammalian expression systems are usually costly and have lower yields. MMP inclusion bodies must undergo the tedious and laborious process of extensive purification and refolding, significantly reducing the yield of MMPs in native conformation. This paper presents a protocol using Rosetta2(DE3)pLysS (hereafter referred to as R2DP) cells to produce matrix metalloproteinase-3 catalytic domain (MMP-3cd), which contains an N-terminal His-tag followed by pro-domain (Hisx6-pro-MMP-3cd) for use in affinity purification. R2DP cells enhance the expression of eukaryotic proteins through a chloramphenicol-resistant plasmid containing codons normally rare in bacterial expression systems. Compared to the traditional cell line of choice for recombinant protein expression, BL21(DE3), purification using this new strain improved the yield of purified Hisx6-pro-MMP-3cd. Upon activation and desalting, the pro domain is cleaved along with the N-terminal His-tag, providing active MMP-3cd for immediate use in countless in vitro applications. This method does not require expensive equipment or complex fusion proteins and describes rapid production of recombinant human MMPs in bacteria.
Most complex eukaryotic proteins undergo elaborate posttranslational modifications after expression, requiring highly assisted protein folding and co-factors to be functional1. Producing large amounts of soluble human protein in a bacterial host remains a significant challenge due to high costs and the lack of robust expression and purification methods, even for smaller-scale laboratory experiments2,3. MMPs, human endopeptidases with large molecular weight, are usually expressed as insoluble inclusion bodies when expressed in E. coli. Extraction of soluble human MMPs often leads to a laborious, time-consuming solubilization and refolding process4.
MMPs have critical roles in both physiological and pathogenic processes. Human MMPs are a family of 23 zinc endopeptidases, categorized by structure and substrate specificity, and differentially expressed in spite of a highly conserved catalytic domain5,6. MMPs are secreted as inactive zymogens, regulated via posttranslational activation and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs)7,8,9,10. Though initially recognized for their role in ECM turnover, MMPs have also been implicated in development, morphogenesis, tissue repair, and remodeling8. Dysregulation of MMPs has been notably linked to cancer along with neurodegenerative, cardiovascular, and fibrotic diseases, among other illnesses5,7.
The development of robust large-scale MMP production methods is critical to ensure the success of future studies of MMP mechanisms through biochemical and cell-based assays. Various MMPs have been previously expressed in bacteria11, including Hisx6-tagged MMPs, without altering MMP activity12,13,14,15. However, these methods include tedious, long steps that might be difficult to replicate.
Mammalian cells can also be used to express many different human proteins while ensuring the proper posttranslational modifications16. Although the mammalian expression system is an ideal choice to produce recombinant human proteins with proper post-translational modifications, the main disadvantages of this method are initial low yields, costly growth media and reagents, long timelines to reach stable expression lines, and risk of contamination with other species such as fungi or bacteria2,11. Moreover, MMP production in mammalian cell lines yields impurities from associated cellular proteins such as TIMPs or fibronectins11. Unlike the slow cell growth observed in mammalian cells, the bacterial expression system offers large-scale protein production in a short period along with simpler media and growth requirements. However, due to the lack of other associated cellular proteins (i.e., TIMPs) in bacterial expression systems, active MMPs at higher concentrations are subject to degradation through autoproteolysis, resulting in poor MMP yield17.
This paper describes a detailed method for bacterial expression, purification, and activation of recombinant Hisx6-pro-MMP-3cd using E. coli as an expression host due to its affordability, simplicity, and success in producing higher yields of MMPs2,3,18. Since E. coli lacks the protein folding machinery and posttranslational processing required for recombinant MMPs and other complex proteins, many E. coli strains have been engineered to overcome these limitations, making E. coli a more suitable host for expression of recombinant human MMP-3cd,19,20. For instance, the R2DP strain used in this study enhances eukaryotic expression by supplying a chloramphenicol-resistant plasmid containing codons rarely used in E. coli.
As described in this protocol, after overexpression of relatively pure inclusion bodies from the pET-3a vector (Figure 1) in R2DP cells, Hisx6-pro-MMP-3 catalytic domain (MMP-3cd) proteins are extracted and denatured4. Hisx6-pro-MMP-3cd3,19 was purified using affinity tag chromatography. Upon refolding and dialysis, the pro-MMP-3cd (zymogen) was activated by 4-aminophenylmercuric acetate (APMA), and SDS-PAGE analysis is used to evaluate yields and the need for further purification5,21. This protocol describes expression, purification, and activation of soluble MMP-3cd as an example. However, it may be also used as a guide for expression of other MMPs and human proteases with similar expression, and activation mechanisms (Figure 2). For other proteins other than MMP-3cd, the reader is advised to determine optimal buffer compositions and methods for their target protein before attempting this protocol.
Figure 1: Plasmid map of the pET-3a-Hisx6-pro-MMP-3cd plasmid. The pET-3a vector includes an ampicillin resistance gene. An N-terminal Hisx6-tag sequence is cloned into the pET-3a-based vector, including pro-MMP-3cd, to yield the pET-3a-Hisx6-pro-MMP-3cd construct under control of T7 promoter between BamHI and NdeI restriction sites. Please click here to view a larger version of this figure.
Figure 2: Bacterial expression of pro-MMP-3cd, purification, refolding, and activation. 1.1: pET-3a-Hisx6-pro-MMP-3cd plasmid was transformed into BL21(DE3) or R2DP Cells. 1.2: Pro-MMP-3cd protein expression was induced using IPTG. 1.3: Chemical lysis and sonication are used to extract Hisx6-pro-MMP-3cd proteins that are mainly insoluble and found in the inclusion bodies. Urea was used to denature and solubilize protein from inclusion bodies. 2.1. Denatured Hisx6-pro-MMP-3cd protein was purified via affinity chromatography purification. 3. The eluted Hisx6-pro-MMP-3cd was slowly refolded during dialysis through gradual removal of urea from the buffer. 4. Finally, refolded MMP-3cd protein was activated using APMA by removing the N-terminal pro-peptide domain. APMA is later removed from the solution through desalting. The numbers correspond to protocol sections describing these steps. Abbreviations: MMP-3cd = Matrix metalloproteinase-3 catalytic domain; APMA = 4-aminophenylmercuric acetate. Please click here to view a larger version of this figure.
1. MMP expression
2. MMP purification and refolding
3. Protein refolding
NOTE: For smaller volumes, dialysis cassettes can be used at a lower risk of sample loss. Dialysis tubing is required if larger volumes are used (see the Table of Materials).
4. Activation
When running samples on SDS-PAGE, because the protein is expressed in the form of insoluble inclusion bodies, the lysed and sonicated fractions should contain little to no Hisx6-pro-MMP-3cd extract, as the protein has not yet been resolubilized in urea. Figure 3 compares the His-tag purification elution fractions of Hisx6-pro-MMP-3cd from BL21(DE3) cells and R2DP cells. Elution fractions were pooled separately for both BL21(DE3) and R2DP cells before dialysis. Fractions from each step were r...
The large-scale production of soluble, human, recombinant MMPs remains a challenging task. Mammalian cells can express functional MMPs at high costs and long wait times, whereas E. coli rapidly produce high quantities of MMP inclusion bodies that must be purified and refolded11,16. R2DP cells significantly increase the yield of MMP inclusion bodies, enabling a more cost-effective and productive MMP refolding process. However, E. coli lack the po...
The authors declare that they have no competing financial interests.
The authors would like to acknowledge Dr. Evette Radisky and Alexandra Hockla at the Mayo Clinic in Jacksonville, Florida, for providing the pET-3a-pro-MMP-3cd plasmid as the template for cloning the Hisx6pro-MMP-3cd gene, and their comments, along with Dr. Paul Hartley from the Nevada Genomics Center at the University of Nevada, Reno, for DNA sequencing. The authors would also like to thank Cassandra Hergenrader for helping with part of protein expression. M.R.-S. would like to thank the NIH-P20 GM103650-COBRE Integrative Neuroscience grant and the UNR R&D mICRO SEED Grant Award.
Name | Company | Catalog Number | Comments |
0.22 µm sterile filter | Sigma Aldrich | SLGP033RS | Used to remove some contaminants from the protein extract before purification, and prevent the Ni-NTA column from clogging |
1 L Erlenmeyer flasks | Thermo Fisher Scientific | S76106F | n/a |
1 L glass bottles | Thermo Fisher Scientific | 06-414-1D | n/a |
1.5 mL microfuge tubes | Thermo Fisher Scientific | 02-682-002 | n/a |
15 mL conical tubes | Thermo Fisher Scientific | 339650 | n/a |
18 G, 1-in. beveled needle | Amazon | B07S7VBHM2 | Used in combination with the dialysis casette |
2 mL desalting column | Thermo Fisher Scientific | 89890 | Removes APMA following activation |
2-(N-Morpholino)ethanesulfonic acid (MES) | Thermo Fisher Scientific | AAA1610422 | n/a |
250 mL conical bottle cushions | Thermo Fisher Scientific | 05-538-53A | Stabilize conical bottles during large-volume centrifugation |
250 mL conical bottles | Thermo Fisher Scientific | 05-538-53 | n/a |
400 mL stirred cell | Sigma Aldrich | UFSC40001 | Re-concentrates a much larger volume than the centrifugal filter unit. Rosetta2(DE3)pLysS cells produce high volumes of protein that may exceed the 15 mL limit of the centrifugal filter unit |
4-aminophenylmercuric acetate (APMA) | Sigma Aldrich | A9563-5G | Activates MMP-3 by cleaving the propeptide |
5 mL syringe | Thermo Fisher Scientific | NC0829167 | Used in combination with the dialysis casette |
50 mL conical tubes | Thermo Fisher Scientific | 339650 | Used for storage in many purification steps |
50 mL re-concentration tube | Sigma Aldrich | UFC901024D | Used for re-concentrating protein samples after dialysis or removing contaminants |
Agar | Thermo Fisher Scientific | BP1423-500 | Buffer ingredient that solidifies autoclaved LB media upon cooling |
Ampicillin | Thermo Fisher Scientific | BP1760-25 | Antibiotic used with pET3a vector; used at 100 µg/mL in LB media |
BamHI | NEB | R3136S | Restriction enzyme to be used with the pET3a vector |
Calcium chloride (CaCl2) | Thermo Fisher Scientific | 600-30-23 | The calcium ion stabilizes MMP structure |
Cell spreaders | Thermo Fisher Scientific | 50-189-7544 | Can be used to spread cells across a petri dish after transformation |
Chloramphenicol | Thermo Fisher Scientific | 22-055-125GM | Antibiotic used with pET3a vector; used at 34 µg/mL in LB media |
Dialysis Buffer 1 | n/a | n/a | 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10 mM CaCl2, 1 µM ZnCl2, 4 M Urea. |
Dialysis Buffer 2 | n/a | n/a | 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10 mM CaCl2, 1 µM ZnCl2, 2 M Urea. |
Dialysis Buffer 3 | n/a | n/a | 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10 mM CaCl2 , 1 µM ZnCl2. |
Dialysis clips | Thermo Fisher Scientific | 68011 | Used in combination with snakeskin dialysis tubing |
Dialysis tubing | Thermo Fisher Scientific | 88243 | Alternative dialysis method that holds much larger sample volumes, but with higher risk of sample loss |
Digest buffer | NEB | B7204S | Buffer used in digesting the pET3a vector |
Disposable cuvettes | Thermo Fisher Scientific | 21-200-257 | Used to measure the bacterial culture OD during growth and expression |
Dithiothreitol (DTT) | Thermo Fisher Scientific | D107125G | Assists with protein denaturation by reducing any disulfide bonds |
DNA assembly mix | NEB | E2621S | Used to ligate the Hisx6-pro-MMP-3cd PCR product and digested pET3a vector |
DNase I | NEB | M0303S | Endonuclease for degrading unfavorable DNA contaminants that could later affect protein purification |
Ethanol | Thermo Fisher Scientific | A995-4 | n/a |
Ethylenediaminetetraacetic acid (EDTA) | Thermo Fisher Scientific | J15694-AE | Used in denaturation. Prevents oxidation and subsequent formation of disulfide bonds |
Gel recovery kit | Promega | A9281 | Isolates and purifies DNA from agarose gels |
Glycerol | Thermo Fisher Scientific | G33-500 | Used for making glycerol stocks, which are frozen at -80 °C |
Gravity flow column | BioRad | 7321010 | Used for Ni-NTA purification of recombinantly His-tagged proteins |
High-transformation efficiency cells | NEB | C2987 | High-transformation efficiency cells with greater chance of success for cloning the N-terminal His-tag into the pET3a-pro-MMP-3cd construct |
HT Elution Buffer | n/a | n/a | 20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 6 M urea, 250 mM imidazole. Adjust pH to 7.4 |
HT Equilibration Buffer | n/a | n/a | 20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 6 M urea. Adjust pH to 7.4 |
HT Regeneration Buffer | n/a | n/a | 20 mM MES, 0.1 M NaCl. Adjust pH to 5.0 |
HT Wash Buffer | n/a | n/a | 20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 6 M urea, 25 mM imidazole. Adjust pH to 7.4 |
Hydrochloric acid (HCl) | Thermo Fisher Scientific | A144C-212 | Used to pH buffers |
Imidazole | Thermo Fisher Scientific | AAA1022122 | Mimics the histidine side group. Used to separate non-specifically binding proteins from the his-tagged target protein |
Inclusion Body Buffer | n/a | n/a | 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, 100 mM NaCl, 5 mM DTT, 2% v/v Triton X 100, 0.5 M Urea. Adjust pH to 8.0 |
Isopropyl-ß-D-thiogalactopyranoside (IPTG) | Thermo Fisher Scientific | FERR0392 | A reagent that induces target gene expression in pET3a. Make 0.5 mL 1 M aliquots, filter sterilize and store in -20 °C |
LB Amp CamR media | n/a | n/a | To be poured into a sterible 1 L bottle or 1 L flask. For 1 L, add 25 g LB Broth. Sterilize by autoclaving. Once cooled to below 50 °C, add ampicillin to 100 µg/mL and chloramphenicol to 34 µg/mL |
LB Amp CamR plates | n/a | n/a | To be poured into sterile petri dishes. Pour until the petri dish lid is completely covered. 1 L of media yields 40-60 plates. For 1 L: 25 g LB Broth, 16 g Agar. Sterilize by autoclaving. Once cooled to below 50 °C, add ampicillin to 100 µg/mL and chloramphenicol to 34 µg/mL |
LB Broth | Thermo Fisher Scientific | BP1426-2 | Pre-mixed with tryptone, yeast extract, and sodium chloride |
Lysis Buffer | n/a | n/a | 50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 100 mM NaCl, 0.133 g/mL lysozyme, 0.49% v/v Triton X-100. Adjust pH to 8.0 |
Lysozyme | MP Biomedicals | 195303 | Used in protein extraction. Enzyme that lyses bacterial cell walls |
Miniprep kit | Promega | A1330 | If successful, extracts the pET3a-pro-MMP-3cd construct from transformants |
NdeI | NEB | R0111S | Restriction enzyme to be used with the pET3a vector |
Ni-NTA resin | Thermo Fisher Scientific | PI88221 | Used to bind recombinant his-tagged proteins. This strong interaction can be displaced with higher concentrations of imidazole |
Nonionic surfactant | Thermo Fisher Scientific | PI28316 | Storage detergent for preventing MMP aggregation. Minimizes interactions between hydrophobic residues on the MMP surface and water molecules, without disrupting catalytic activity. |
PCR mix | NEB | M0492S | A PCR reagent for inserting an N-terminal his-tag into the pET3a-pro-MMP-3cd vector |
pET plasmid | Addgene | n/a | The pET3a vector offers ampicillin resistance, inducible expression of a target gene, and sequencing with T7 primers |
Petri dishes | VWR | 25384-342 | Used for plating transformants on LB agar media |
R2DP cells | Novagen | 714033 | BL21 derivatives with enhanced expression of eukaryotic proteins. Contain tRNAs of codons found to be rare in e. coli |
SOC growth media | NEB | B9020S | Non-selective growth media for rapid growth during transformation |
Sodium chloride (NaCl) | Thermo Fisher Scientific | BP358-1 | Used in buffers and helps with protein stability |
Sodium deoxycholate | Thermo Fisher Scientific | PI89905 | Detergent used in protein extraction. Lyses cell walls |
Solubilization Buffer | n/a | n/a | 20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 10 mM DTT, 6 M Urea. Adjust pH to 8.0 |
Tris base | Thermo Fisher Scientific | BP152-1 | Common buffer used in the physiological pH range. Temperature-sensitive |
Triton X-100 | Thermo Fisher Scientific | M1122980101 | Detergent used for cell lysis |
Urea | Thermo Fisher Scientific | AAJ75826A7 | First chaotropic agent for disrupting protein secondary structure |
Zinc chloride (ZnCl2) | Thermo Fisher Scientific | AAA162810E | Stabilizes MMP structure. The zinc ion is found in the catalytic site of MMP-3 |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved